Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2003

View Archived Issues

Beneficial effects reported for duloxetine in primary fibromyalgia

LJP-394 well tolerated in SLE patients with renal disease

Milnacipran as a potential therapy for FMS

Immunomodulatory effects of OM-89 in rheumatoid arthritis patients

Studies on lumiracoxib in rheumatoid arthritis presented at ACR meeting

Immunomodulating activity reported for LymphoStat-B in monkeys and SLE patients

Sankyo describes the isolation of a 2'-PDE inhibitor with utility in viral infections

First North American trial of Adhibit

Levaquin approved for five-day treatment of CAP

Millennium and Bayer alliance concludes

New inhibitors of ZAP-70, FAK and/or Syk designed at Novartis

Indian group identifies new antiallergic/antiasthmatic agents

Servier team presents new 5-HT2C antagonists for anxiety and other disorders

Apotex researchers prepare and test new factor XIIIa inhibitors

Two series of PDE7 inhibitors and their use presented by Warner-Lambert (Pfizer) scientists

Novel HIV integrase inhibitors claimed by Merck

Novartis describes new CCR3 antagonists with utility in asthma therapy

Sankyo intensifies development of anticancer drugs

Sifrol approved for the treatment of Parkinson's disease

Raptiva approved for chronic, moderate to severe plaque psoriasis

Approvable letter received for Ariflo

Canadian approval for Gleevec for newly diagnosed Ph+ CML

European enrollment commences in phase II trial for DAC:GLP-1

Development of KW-6002 temporarily suspended

Prodrugs of CO/CO2 associated with clinical and radiographic improvement in arthritis

Targeted therapy of AML with anti-FLT3 antibody under evaluation

Anticytokine drug in development at Kowa for oral therapy of arthritis

Microbially produced inhibitor of bacteria-specific enzyme discovered

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...